Janux Therapeutics (JANX) Proxy Filing summary

Executive summary

• Annual meeting scheduled for June 11, 2025, to be held virtually for stockholders of record as of April 17, 2025.

• Proxy materials, including the Notice of Meeting, Proxy Statement, and Annual Report or Form 10-K, are available online, with paper copies available upon request by May 30, 2025.

Voting matters and shareholder proposals

• Election of three Class I director nominees for three-year terms until the 2028 Annual Meeting: Ronald Barrett, Ph.D., David Campbell, Ph.D., and Winston Kung.

• Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2025.

• Advisory vote on executive compensation (Say-On-Pay) as disclosed in the proxy statement.

• Advisory vote on the preferred frequency of future Say-On-Pay votes.

• Provision to conduct any other business properly brought before the meeting.

Board of directors and corporate governance

• Board recommends voting for all director nominees and for all proposals, including a one-year frequency for Say-On-Pay votes.